Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Wisconsin, Madison Pfizer Genentech |
---|---|
Information provided by: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT00581789 |
Condition | Intervention | Phase |
---|---|---|
Non Small Cell Lung Cancer |
Drug: erlotinib, sunitinb |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Phase I Study of Erlotinib and Sunitinib in Non-Small Cell Lung Cancer |
Estimated Enrollment: | 12 |
Study Start Date: | August 2007 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
|
Drug: erlotinib, sunitinb
erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Cancer Connect | 800-622-8922 | uwccc@uwccc.wisc.edu |
United States, Wisconsin | |
University of Wisconsin Carbone Comprehensive Cancer Center | Recruiting |
Madison, Wisconsin, United States, 53792 |
Principal Investigator: | Anne Traynor, MD | University of Wisconsin, Madison |
Responsible Party: | University of Wisconsin ( Anne Traynor, MD ) |
Study ID Numbers: | H-2007-0063, CO05507 |
Study First Received: | December 19, 2007 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00581789 History of Changes |
Health Authority: | United States: Institutional Review Board |
non small cell lung cancer sunitinib erlotinib phase 1 |
Erlotinib Thoracic Neoplasms Respiratory Tract Diseases Sunitinib Lung Neoplasms Lung Diseases |
Non-small Cell Lung Cancer Angiogenesis Inhibitors Protein Kinase Inhibitors Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Erlotinib Respiratory Tract Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors Angiogenesis Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |
Carcinoma Neoplasms Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Sunitinib Therapeutic Uses Lung Diseases Growth Inhibitors Angiogenesis Modulating Agents Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |